Status:
RECRUITING
Prognostic Value Of Short-Term Follow-up Biomarkers After Discharge In hOspitalized Patients With Acute Heart Failure
Lead Sponsor:
Wonju Severance Christian Hospital
Collaborating Sponsors:
Roche diagnostics Korea
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Several surrogate biomarkers including natriuretic peptide(NP), and growth differentiation factor-15(GDF-15) and ST2 has prognostic significance in heart failure(HF), and reductions in its value may p...
Eligibility Criteria
Inclusion
- the diagnosis of Heart failure requires the following
- heart failure with reduced ejection fraction ( A 'reduced' ejection fraction (EF) defined as EF \<40%): the presence of symptoms and/or signs of HF
- heart failure with preserved ejection fraction ( A 'preserved' EF defined as EF≥ 40%) requires the all of the followings: a) the presence of symptoms and/or signs of HF b) elevated levels of natriuretic peptides (defined as B-type natriuretic peptide (BNP) \>100pg/ml and/or N terminal B-type natriuretic peptide (NT-proBNP) \>300pg/ml) c) any structural heart disease (left atrial volume index ≥ 34 mL/m2, left atrial dimension ≥ 50 mm, posterior or septal wall thickness ≥ 11mm)
Exclusion
- any severe condition limiting life less than 3 months
- the patient is not ready to contact by telephone at the end of the study
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04437628
Start Date
February 1 2021
End Date
December 31 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Wonju College of Medicine
Wŏnju, Gangwondo, South Korea, 26426